Galmed Pharmaceuticals(GLMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GLMD Galmed Pharmaceuticals

Closed Good Friday 04-17 16:00:00 EDT

1.38

+0.02

+1.47%

High1.44	Low1.31	Vol33.17K
Open1.32	D1 Closing1.36	Amplitude9.47%
Mkt Cap3.12M	Tradable Cap2.02M	Total Shares2.26M
T/O45.11K	T/O Rate2.27%	Tradable Shares1.46M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"GLMD","market":"US","secType":"STK","nameCN":"Galmed Pharmaceuticals","latestPrice":1.38,"timestamp":1744920000000,"preClose":1.36,"halted":0,"volume":33171,"delay":0,"floatShares":1461300,"shares":2258034,"eps":-8.075657,"marketStatus":"Closed Good Friday","change":0.02,"latestTime":"04-17 16:00:00 EDT","open":1.32,"high":1.4388,"low":1.31,"amount":45112.05324,"amplitude":0.094706,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-8.075657,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1394683200000,"exchange":"NASDAQ","adjPreClose":1.36,"preHourTrading":{"tag":"盘前","latestPrice":1.42,"preClose":1.36,"latestTime":"09:10 EDT","volume":2193,"amount":3115.7196624,"timestamp":1744895446208},"volumeRatio":0.15745060182312062,"impliedVol":5.6279,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/GLMD","defaultTab":"news","newsList":[{"id":"2528712372","title":"BRIEF-Galmed Pharmaceuticals Launches VCU Collaboration To Tackle Drug Resistance In Gi Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2528712372","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528712372?lang=en_us&edition=full_marsco","pubTime":"2025-04-17 20:51","pubTimestamp":1744894312,"startTime":"0","endTime":"0","summary":"BRIEF-Galmed Pharmaceuticals Launches VCU Collaboration To Tackle Drug Resistance In Gi CancersApril 17 (Reuters) - Galmed Pharmaceuticals Ltd GLMD.O:GALMED PHARMACEUTICALS LAUNCHES VCU COLLABORATION ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nTUAC2851J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GLMD"],"gpt_icon":0},{"id":"2528114187","title":"Galmed Pharmaceuticals Launches Vcu Collaboration to Tackle Drug Resistance in Gi Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2528114187","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528114187?lang=en_us&edition=full_marsco","pubTime":"2025-04-17 20:30","pubTimestamp":1744893004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nTUAC2851J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GLMD","BK4139"],"gpt_icon":0},{"id":"2527412205","title":"Galmed Pharmaceuticals Unveils New Blood Markers for Aramchol","url":"https://stock-news.laohu8.com/highlight/detail?id=2527412205","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527412205?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 21:28","pubTimestamp":1744723682,"startTime":"0","endTime":"0","summary":"An update from Galmed Pharmaceuticals ( ($GLMD) ) is now available. On April 15, 2025, Galmed Pharmaceuticals announced the discovery of novel phar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/galmed-pharmaceuticals-unveils-new-blood-markers-for-aramchol?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/galmed-pharmaceuticals-unveils-new-blood-markers-for-aramchol?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GLMD","BK4139"],"gpt_icon":0},{"id":"2527415023","title":"Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2527415023","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527415023?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 20:30","pubTimestamp":1744720200,"startTime":"0","endTime":"0","summary":"Analysis of blood samples from patients treated withAramchol in ARMOR  provides new and important insights into the biochemical and physiological effects of the drug.The pharmacodynamic signature associated with Aramchol treatment revealed a decrease in markers of chronic systemic inflammation, oxidative and cardiac stress, and atherosclerotic plaque pathogenesis.TEL AVIV, Israel, April 15, 2025 /PRNewswire/ --Galmed Pharmaceuticals Ltd.  , a clinical-stage biopharmaceutical company dedicated to developing novel treatments for liver, cardiometabolic, and gastrointestinal oncology indications, today announces the unveiling of novel pharmacodynamic  blood markers for its lead compound, Aramchol, the industry's most clinically advanced SCD1 inhibitor. These newly identified biomarkers shed fresh light on Aramchol's potential far beyond its role in NASH  therapy—offering a deeper understanding of the drug candidate's biochemical impact and presenting an exciting opportunity to enhance clin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/galmed-unveils-novel-pharmacodynamic-blood-123000723.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/galmed-unveils-novel-pharmacodynamic-blood-123000723.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GLMD","PD","IE0031619046.USD","IE00B7SZL793.SGD","BK4023","LU1169589451.USD","BK4157","LU1169590202.USD","IE00B66KJ199.SGD","AEIS","IE00B19Z4B17.USD","BK4139"],"gpt_icon":0},{"id":"2526636875","title":"Galmed Pharmaceuticals Ltd: Aramchol Meglumine Received Nce Patent Protection Extending Until 2035","url":"https://stock-news.laohu8.com/highlight/detail?id=2526636875","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526636875?lang=en_us&edition=full_marsco","pubTime":"2025-04-10 20:02","pubTimestamp":1744286553,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nFWN3QO146:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GLMD"],"gpt_icon":0},{"id":"2526565563","title":"Galmed Announces Positive Part 1 Results From the Am-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced Scd1 Inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2526565563","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526565563?lang=en_us&edition=full_marsco","pubTime":"2025-04-10 20:02","pubTimestamp":1744286553,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nFWN3QO146:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GLMD","BK4139"],"gpt_icon":0},{"id":"2526214565","title":"Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2526214565","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526214565?lang=en_us&edition=full_marsco","pubTime":"2025-04-10 20:00","pubTimestamp":1744286400,"startTime":"0","endTime":"0","summary":"– AM-001 Study represents a pivotal milestone in Galmed's transition to Aramchol Meglumine, an improved formulation of its lead compound in advanced clinical development– Aramchol Meglumine, a New Chemical Entity  protected by patents until 2035, is being developed both as a standalone agent and in novel drug combinations for multiple indications influenced by fatty acid metabolism– Initial findings suggest that the new Aramchol Meglumine formulation offers higher bioavailability than Aramchol free acid and that a once-daily, oral 200 mg dose is likely to be optimal for future trials, supporting improved patient compliance and potentially lowering manufacturing costs. TEL AVIV, Israel, April 10, 2025 /PRNewswire/ --Galmed Pharmaceuticals Ltd.  , a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, and gastrointestinal oncology indications, today announced positive preliminary results from Part 1 of the Ph1 Bioavailability AM-001 Study of Aramchol Meglumine.\"Ara","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/galmed-announces-positive-part-1-120000753.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/galmed-announces-positive-part-1-120000753.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AM","AEIS","BK4157","IE00B66KJ199.SGD","GLMD","BK4144","BK4139","IE00B7SZL793.SGD","IE0031619046.USD","IE00B19Z4B17.USD"],"gpt_icon":0},{"id":"2525833780","title":"BUZZ-Galmed Pharmaceuticals falls after Maxim downgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2525833780","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525833780?lang=en_us&edition=full_marsco","pubTime":"2025-04-05 00:10","pubTimestamp":1743783044,"startTime":"0","endTime":"0","summary":"BUZZ-Galmed Pharmaceuticals falls after Maxim downgrade** Shares of Israel-based drug developer Galmed Pharmaceuticals GLMD.O down 5.5% to $1.38** Maxim Group cuts rating from to \"hold\" from \"buy,\" and removes PT ** Downgrading GLMD due to the lack of clarity on the path forward and strategic positioning - Maxim** GLMD may also potentially require a capital raise to commence a clinical trial; under current market conditions, financing will likely be difficult and significantly dilutive, Maxim says** Up to last close, GLMD had fallen over 52% YTD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250404:nL3N3QI145:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLMD"],"gpt_icon":0},{"id":"2524420237","title":"Galmed Pharmaceuticals Cut to Hold From Buy by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2524420237","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524420237?lang=en_us&edition=full_marsco","pubTime":"2025-04-04 21:30","pubTimestamp":1743773400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GLMD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 04, 2025 09:30 ET (13:30 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLMD","BK4139"],"gpt_icon":0},{"id":"2524205449","title":"Galmed downgraded to Hold from Buy at Maxim","url":"https://stock-news.laohu8.com/highlight/detail?id=2524205449","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524205449?lang=en_us&edition=full_marsco","pubTime":"2025-04-04 19:50","pubTimestamp":1743767407,"startTime":"0","endTime":"0","summary":"Maxim analyst Naz Rahman downgraded Galmed (GLMD) to Hold from Buy. Published first on TheFly – the ultimate source for real-time, market-moving br...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/galmed-downgraded-to-hold-from-buy-at-maxim?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/galmed-downgraded-to-hold-from-buy-at-maxim?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GLMD","BK4139"],"gpt_icon":0},{"id":"2524461203","title":"Galmed Pharmaceuticals Ltd : Maxim Group Cuts to Hold From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2524461203","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524461203?lang=en_us&edition=full_marsco","pubTime":"2025-04-04 19:38","pubTimestamp":1743766685,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250404:nFWN3QI19F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GLMD"],"gpt_icon":0},{"id":"2524445020","title":"Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2524445020","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524445020?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 04:10","pubTimestamp":1743624600,"startTime":"0","endTime":"0","summary":"TEL AVIV, Israel, April 2, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd.  , a clinical-stage biopharmaceutical company focused on liver, cardiometabolic diseases and GI oncological indications, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2024, with the U.S. Securities and Exchange Commission .Shareholders can obtain copies of Galmed's Annual Report on Form 20-F, free of charge, by making a request within a reasonable period of time to Galmed's Investor Relations Department at investor.relations@galmedpharma.com.We are a clinical stage biopharmaceutical company focused on the development of Aramchol for oncological indications outside of liver disease. In addition, as part of our growth strategy, we are actively pursuing opportunities to expand and diversify our product pipeline specifically targeting cardiometabolic indications and other innovative product candidates that align with our core expertise in drug development.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/galmed-pharmaceuticals-ltd-files-annual-201000554.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/galmed-pharmaceuticals-ltd-files-annual-201000554.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","GLMD"],"gpt_icon":0},{"id":"2520145991","title":"Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in Nash/Mash Combination Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2520145991","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520145991?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 20:55","pubTimestamp":1742475349,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nFWN3Q313J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GLMD","BK4139"],"gpt_icon":0},{"id":"2520526924","title":"Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2520526924","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520526924?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 20:55","pubTimestamp":1742475300,"startTime":"0","endTime":"0","summary":"TEL AVIV, Israel, March 20, 2025 /PRNewswire/ --Galmed Pharmaceuticals Ltd.  , a clinical-stage biopharmaceutical company focused on liver, cardiometabolic diseases and GI oncological indications, today announced the grant of a new patent related to its lead compound, Aramchol. The patent covers the use of a combination therapy of Aramchol and Resmetirom  for the treatment of non-alcoholic steatohepatitis , also known as metabolic dysfunction-associated steatohepatitis , and liver fibrosis.With this latest patent,Galmed is strengthening and extending Aramchol's patent protection through September 2039, securing long-term market exclusivity for its novel NASH therapy.This 15-year exclusivity runway is a significant intellectual property milestone for Galmed, positioning the Company to fully capitalize on Aramchol's commercial potential in the coming years.This differentiated mechanism sets Aramchol apart from other NASH therapies in development, which often target metabolic aspects such","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/galmed-pharmaceuticals-secures-patent-grant-125500496.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/galmed-pharmaceuticals-secures-patent-grant-125500496.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GLMD","BK4139"],"gpt_icon":0},{"id":"2483288376","title":"Galmed Pharmaceuticals: Q3 Earnings Snapshot","url":"https://stock-news.laohu8.com/highlight/detail?id=2483288376","media":"Associated Press Finance","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483288376?lang=en_us&edition=full_marsco","pubTime":"2024-11-15 21:29","pubTimestamp":1731677386,"startTime":"0","endTime":"0","summary":"RAMAT GAN, Israel  — RAMAT GAN, Israel  — Galmed Pharmaceuticals Ltd.  on Thursday reported a loss of $1.9 million in its third quarter.The Ramat Gan, Israel-based company said it had a loss of $2.31 per share.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/galmed-pharmaceuticals-q3-earnings-snapshot-132946111.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GLMD"],"gpt_icon":0},{"id":"2483354361","title":"Galmed Pharmaceuticals Embraces Market with New Sales Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2483354361","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483354361?lang=en_us&edition=full_marsco","pubTime":"2024-11-15 06:47","pubTimestamp":1731624428,"startTime":"0","endTime":"0","summary":"Galmed Pharmaceuticals (GLMD) has released an update. Galmed Pharmaceuticals Ltd. has entered into a sales agreement with JonesTrading Institutiona...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/galmed-pharmaceuticals-embraces-market-with-new-sales-agreement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/galmed-pharmaceuticals-embraces-market-with-new-sales-agreement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GLMD"],"gpt_icon":0},{"id":"2483356254","title":"Galmed files $200M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2483356254","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483356254?lang=en_us&edition=full_marsco","pubTime":"2024-11-15 06:15","pubTimestamp":1731622510,"startTime":"0","endTime":"0","summary":"17:14 EST Galmed (GLMD) files $200M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaking fi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/galmed-files-200m-mixed-securities-shelf?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/galmed-files-200m-mixed-securities-shelf?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GLMD","BK4139"],"gpt_icon":0},{"id":"2483809356","title":"Galmed Pharmaceuticals Ltd Files for Mixed Shelf of up to $200 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2483809356","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483809356?lang=en_us&edition=full_marsco","pubTime":"2024-11-15 06:12","pubTimestamp":1731622341,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nFWN3ML1I5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GLMD"],"gpt_icon":0},{"id":"2477081413","title":"Galmed Pharmaceuticals Amends Equity Purchase Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2477081413","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477081413?lang=en_us&edition=full_marsco","pubTime":"2024-10-22 04:48","pubTimestamp":1729543712,"startTime":"0","endTime":"0","summary":"Galmed Pharmaceuticals (GLMD) has released an update. Galmed Pharmaceuticals has amended its Standby Equity Purchase Agreement with YA II PN, LTD.,...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/galmed-pharmaceuticals-amends-equity-purchase-agreement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/galmed-pharmaceuticals-amends-equity-purchase-agreement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4139","BK4215","EQR","GLMD","BK4588"],"gpt_icon":0},{"id":"2477984819","title":"Galmed files to sell 1M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2477984819","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477984819?lang=en_us&edition=full_marsco","pubTime":"2024-10-22 04:26","pubTimestamp":1729542364,"startTime":"0","endTime":"0","summary":"16:22 EDT Galmed (GLMD) files to sell 1M shares of common stock for holders Published first on TheFly – the ultimate source for real-time, market-m...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/galmed-files-to-sell-1m-shares-of-common-stock-for-holders?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/galmed-files-to-sell-1m-shares-of-common-stock-for-holders?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GLMD","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.galmedpharma.com","stockEarnings":[{"period":"1week","weight":0.0952},{"period":"1month","weight":-0.4502},{"period":"3month","weight":-0.5241},{"period":"6month","weight":-0.6368},{"period":"1year","weight":-0.6878},{"period":"ytd","weight":-0.5674}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.031845},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.047865},{"month":3,"riseRate":0.272727,"avgChangeRate":-0.072855},{"month":4,"riseRate":0.5,"avgChangeRate":-0.009252},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.10707},{"month":6,"riseRate":0.727273,"avgChangeRate":0.149358},{"month":7,"riseRate":0.454545,"avgChangeRate":-0.092766},{"month":8,"riseRate":0.272727,"avgChangeRate":-0.043331},{"month":9,"riseRate":0.454545,"avgChangeRate":0.030103},{"month":10,"riseRate":0.181818,"avgChangeRate":-0.150001},{"month":11,"riseRate":0.363636,"avgChangeRate":-0.02458},{"month":12,"riseRate":0.454545,"avgChangeRate":0.05936}],"exchange":"NASDAQ","name":"Galmed Pharmaceuticals","nameEN":"Galmed Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Galmed Pharmaceuticals(GLMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Galmed Pharmaceuticals(GLMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Galmed Pharmaceuticals,GLMD,Galmed Pharmaceuticals股票,Galmed Pharmaceuticals股票老虎,Galmed Pharmaceuticals股票老虎国际,Galmed Pharmaceuticals行情,Galmed Pharmaceuticals股票行情,Galmed Pharmaceuticals股价,Galmed Pharmaceuticals股市,Galmed Pharmaceuticals股票价格,Galmed Pharmaceuticals股票交易,Galmed Pharmaceuticals股票购买,Galmed Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Galmed Pharmaceuticals(GLMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Galmed Pharmaceuticals(GLMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction